At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
Elpipodect +1 moredrug
Likely dose
Elpipodect 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis
In Brief
A Phase 1 clinical trial evaluating Elpipodect and Placebo for Alzheimer's Disease. Completed, enrolled 29 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartJul 2022
Primary CompletionJan 2023
TodayJul 2026
First PostedFeb 7, 2022
Enrollment StartJul 1, 2022
Primary CompletionJan 10, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.4 years ago
Interventions
Elpipodectdrug
MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
Placebodrug
MK-8189 matching placebo administered orally QD